Stock vs Stock Comparison

AstraZeneca PLC vs AbbVie Inc.

AZN wins the Tale of the Tape 6–2.

AZN$177.45
ABBV$215.40

🏆 Tale of the Tape

62
AZNABBV
17.4%Profitability (Net Margin)6.9%
27.9xValuation (P/E)106.2x
13.3%Efficiency (ROIC)8.3%
7/9Health (Piotroski F)7/9
3.9Safety (Altman Z)2.0
8.6%Growth (Rev YoY)8.6%
1.61Risk (Sharpe 1Y)0.61
1.34xBalance Sheet (D/E)-42.50x
2.59%FCF Yield4.23%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.465
252-Day Correlation
0.275
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricAZNABBV
Market Cap$287.9B$384.7B
P/E Ratio27.9x106.2x
Forward P/E23.1x13.4x
P/B6.08x-57.80x
Dividend Yield1.70%3.18%
Beta0.220.30

Quantitative Metrics

MetricAZNABBV
DCF Fair Value$132.90$126.26
DCF Upside-34.3%-38.9%
Piotroski F7/97/9
Altman Z3.942.01
Beneish M-2.87
FCF Yield2.59%4.23%
Net Debt/EBITDA1.0x3.0x
ROIC13.3%8.3%
WACC7.7%7.4%
ROIC – WACC5.6pp0.8pp
Gross Margin81.9%70.2%
Net Margin17.4%6.9%
Rev Growth YoY8.6%8.6%
Sharpe (1Y)1.610.61
Max Drawdown 3Y-27.9%
FCF Payout Ratio57%65%

AZN Price

Loading chart...

ABBV Price

Loading chart...

ETF Exposure

AZN found in:

VGK1.81%
VSGX1.01%
VEA0.90%
SPDW0.88%
CWI0.78%
VEU0.71%
VXUS0.65%
VT0.25%

ABBV found in:

XLV7.07%
IYH6.86%
VHT6.04%
HDV5.61%
SCHD3.53%
DGRO2.52%
DGRW1.99%
MGV1.85%
VIG1.68%
VYM1.56%
NOBL1.49%
VTV1.46%
SDY1.42%
IWF1.39%
SCHV1.38%
VONG1.21%
XBI1.09%
ESGV0.78%
SPYV0.71%
IVV0.69%
SPLG0.68%
SCHX0.66%
SCHB0.62%
ITOT0.61%
VOO0.60%
SPY0.59%
VONE0.57%
SPTM0.55%
VTI0.54%
SPYG0.50%
URTH0.48%
ACWI0.41%
VFVA0.41%
VT0.33%
QUS0.32%
VFMV0.25%
RSP0.19%
ONEO0.03%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

AZN vs ABBV: Head-to-Head Analysis

AstraZeneca PLC (AZN) and AbbVie Inc. (ABBV) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, AZN leads 6–2 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, AZN generates a return on invested capital (ROIC) of 13.3% compared to ABBV's 8.3%. This suggests AZN is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between AZN and ABBV is 0.465, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

AZN appears in 8 ETFs tracked by SecuritiesDB, while ABBV appears in 38 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, AZN or ABBV?

Our quantitative analysis compares AZN and ABBV across nine fundamental dimensions. AZN wins the Tale of the Tape 6–2. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are AZN and ABBV correlated?

The 252-day correlation between AZN and ABBV is 0.465. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.